Publication:
Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients

Simple item page
dc.contributor.authorATASOY, BESTE MELEK
dc.contributor.authorsAtasoy, B. M.; Dane, F.; Cetin, I. Alsan; Ozgen, Z.; Kefeli, A. Ucuncu; Ibrahimov, R.; Turhal, N. S.; Abacioglu, U.; Turkeri, L.
dc.date.accessioned2022-03-13T12:45:47Z
dc.date.available2022-03-13T12:45:47Z
dc.date.issued2014
dc.description.abstractWe aimed to determine the efficacy and the toxicity of low dose weekly gemcitabine with radiation therapy in medically unfit muscle-invasive bladder cancer patients. Twenty-six patients were included into the retrospective analysis. Weekly gemcitabine was administered 75 mg/m(2) with a median dose of 63 Gy radiation therapy. Clinical target volume was defined as the urinary bladder only in conformal treatment planning. Median follow-up was 51 months (range 14-118 months). Complete response rate was 62.5 %. The 5-year local progression-free survival, disease-specific survival and overall survival rates were 40.6, 59.5 and 58.5 %, respectively. Concurrent chemotherapy was continued in 80.7 % of patients without any interruption. Gemcitabine was stopped due to grade 3 thrombocytopenia (n = 1), cardiac angina (n = 1), chronic obstructive pulmonary disease exacerbation (n = 1) or patients' reluctance (n = 2). Low dose weekly gemcitabine with concurrent radiotherapy is a tolerable regimen and have comparable outcomes with platinum-based combined treatments in muscle-invasive bladder cancer. Prospective randomized trials can help in understanding the safety and efficacy of this treatment specially in medically unfit patients.
dc.identifier.doi10.1007/s12094-013-1047-8
dc.identifier.eissn1699-3055
dc.identifier.issn1699-048X
dc.identifier.pubmed23615982
dc.identifier.urihttps://hdl.handle.net/11424/237844
dc.identifier.wosWOS:000329582700013
dc.language.isoeng
dc.publisherSPRINGER-VERLAG ITALIA SRL
dc.relation.ispartofCLINICAL & TRANSLATIONAL ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBladder cancer
dc.subjectConcurrent gemcitabine
dc.subjectMedically unfit patients
dc.subjectRadiotherapy
dc.subjectCOMBINED-MODALITY PROGRAM
dc.subjectRADIATION-THERAPY
dc.subjectPHASE-I
dc.subjectNEOADJUVANT CHEMOTHERAPY
dc.subjectORGAN PRESERVATION
dc.subjectRADIOTHERAPY
dc.subjectTRIAL
dc.subjectCISPLATIN
dc.titleConcurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients
dc.typearticle
dspace.entity.typePublication
local.avesis.ide7e29024-e00d-4018-a663-e9be026d0015
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages5
oaire.citation.endPage95
oaire.citation.issue1
oaire.citation.startPage91
oaire.citation.titleCLINICAL & TRANSLATIONAL ONCOLOGY
oaire.citation.volume16
relation.isAuthorOfPublication22ce1b48-93da-4e88-a61e-be24b5e6122a
relation.isAuthorOfPublication.latestForDiscovery22ce1b48-93da-4e88-a61e-be24b5e6122a

Files

Collections

Research Outputs